A Study to Evaluate CTX-712 in Advanced, Relapsed or Refractory Malignant Cancer Patients
- Conditions
- Advanced,relapsed or refractory cancers
- Registration Number
- JPRN-jRCT2080224127
- Lead Sponsor
- Chordia Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 79
1) Subjects must have an advanced, relapsed or refractory cancer
- For a cohort of hematological cancers,subjects must have an MDS, CMML or AML (excluding APL) according to World Health Organization (WHO) criteria.
- As for MDS, subjects must be considered an intermediate, high, or very high risk according to the Revised International Prognostic Scoring System (IPSS-R)
2) Subjects must relapse or refractory to standard therapies, or not eligible for standard therapies.
3) Subjects must be an eastern cooperative oncology group (ECOG) performance status of 0 or 1
4) Subjects must have more than 90 days life expectancy
5) Subjects must have adequate major organ functions
1) Patients with uncontrolled complications
2) Patients with active multiple primary cancers that require specific treatments
3) In a cohort of hematologic cancer patients, those who have received allogenic hematopoietic stem cell transplantation
4) Patients having a medical history of congenital retinal degenerative disease,optic nerve or retinal diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method